Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...

Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...

Leading scientists are advocating for annual prostate cancer screening for men with BRCA1 and BRCA2 gene mutations. Experts at the London-based Institute of Cancer Research (ICR) state that the ...

Expanded indication for AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...

Figure 1: Photograph of agarose gel electrophoresis showing PCR-RFLP of BRCA2 and HOXB13 gene mutation mentioned in Table 1. (A) Here P1, P3, and P4 shows the positive results for BRCA2 gene mutation.

Expanded indication for AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...

The UK National Screening Committee has opened a 12-week public consultation on whether and how prostate cancer screening ...